Cellicon Valley '23: The Future of Cell and Gene Therapies

---

LIVEAAPACMECNEOpioid

Thursday, June 22, 2023, 11:20 AM - 3:40 PM, Irvine Auditorium / AJI Media Livecast, Philadelphia, PA

As home to the first FDA-approved cell and gene therapies, Penn Medicine and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with the University of Pennsylvania ranking 1st among global universities for CAR-T cell patents, according to Nature Biotechnology. CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The approvals of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy, hematologic malignancies, and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and weigh in on current applications, best practices, novel strategies and future developments for CAR T cells. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care and understanding new strategies to optimize and improve CAR T cell therapies. Participants will leave with up-to-date, practical information which will have immediate clinical application, and an understanding of critical research initiatives that are rapidly driving this field forward. Research participants will leave with the technical and scientific background on the current state, and where the latest scientific advances may take the field.

1. Identify current application of CAR T-cell therapy including: disease indication, accurate patient selection, manufacturing and treatment administration for adult and pediatric patients
2. Describe the latest for CAR T-Cell Therapy for T Cell ALL, multiple myeloma and CLL
3. List challenges and opportunities for equitable patient access
4. Explain the risk of malignancies and curative therapies for hemoglobinopathies
5. Identify the current status of globalization of cell and gene therapies
6. Describe the latest targets and technologies for CARs
7. Define toxicity and its management
8. Identify mechanisms of resistance and how to overcome it
9. List recent advances in cell therapy for solid tumors
10. Describe chimeric antigen receptor T Cells for T Cell malignancies

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit
Physicians: Penn Medicine designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (2.25 hours), Non-Physician Attendance / Participation (2.25 hours), NCPD Hours (ANCC) (2.25 hours), Opioid Education (2.25 hours), American Academy of Physician Assistants (2.25 hours)

Mitigation of Relevant Financial Relationships

Penn Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.